Meds Apotek AB (publ) (OSTO:MEDS) EBIT: kr5 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:MEDS Meds Apotek AB (publ) OSTO:MEDS
11 GF Score
Price kr25.20
! 2 Warning Signs
View Full Analysis

What is Meds Apotek AB (publ) EBIT?

Meds Apotek AB (publ) OSTO:MEDS +18.31% 11 EBIT is kr5 Mil as of Jun. 2026. GuruFocus rates OSTO:MEDS with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Meds Apotek AB (publ)'s earnings before interest and taxes (EBIT) for the three months ended in Jun. 2026 was kr6 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was kr5 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Meds Apotek AB (publ)'s annualized ROC % for the quarter that ended in Jun. 2026 was 22.81%. Meds Apotek AB (publ)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 58.05%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Meds Apotek AB (publ)'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 1.29%.


Meds Apotek AB (publ)  (OSTO:MEDS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Meds Apotek AB (publ)'s annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2026 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=22.576 * ( 1 - 0.93% )/( (91.645 + 104.487)/ 2 )
=22.3660432/98.066
=22.81 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=287.063 - 123.874 - ( 71.544 - max(0, 151.839 - 243.991+71.544))
=91.645

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=274.506 - 103.364 - ( 66.655 - max(0, 133.334 - 233.728+66.655))
=104.487

Note: The Operating Income data used here is four times the quarterly (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Meds Apotek AB (publ)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2026  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=23.092/( ( (20.036 + max(18.451, 0)) + (17.436 + max(23.634, 0)) )/ 2 )
=23.092/( ( 38.487 + 41.07 )/ 2 )
=23.092/39.7785
=58.05 %

where Working Capital is:

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(28.846 + 135.674 + 1.042) - (123.874 + 0 + 23.237)
=18.451

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(24.48 + 128.844 + 1.265) - (103.364 + 0 + 27.591)
=23.634

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Meds Apotek AB (publ)'s Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2026 )
=5.194/403.743
=1.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Meds Apotek AB (publ) EBIT Related Terms


Meds Apotek AB (publ) EBIT Historical Data

* Premium members only.

The historical data trend for Meds Apotek AB (publ)'s EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Meds Apotek AB (publ) EBIT Chart

Meds Apotek AB (publ) Annual Data
Trend Dec21 Dec23 Dec24 Dec25
EBIT
0.00 -47.68 -7.20 -1.98

Meds Apotek AB (publ) Quarterly Data
Dec21 Jun22 Dec23 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -1.64 -5.60 -0.31 5.33 5.77

OSTO:MEDS vs AMZN, BABA, PDD: EBIT Comparison

For the Internet Retail subindustry, Meds Apotek AB (publ)'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Meds Apotek AB (publ) EV-to-EBIT vs Retail - Cyclical Industry

For the Retail - Cyclical industry and Consumer Cyclical sector, Meds Apotek AB (publ)'s EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Meds Apotek AB (publ)'s EV-to-EBIT falls into.


OSTO:MEDS
11GF Score
Meds Apotek AB (publ) OSTO:MEDS
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Meds Apotek AB (publ) EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr5 Mil mean?
Meds Apotek AB (publ) (OSTO:MEDS) has a EBIT of kr5 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Meds Apotek AB (publ).
Is Meds Apotek AB (publ)'s EBIT too high?
Meds Apotek AB (publ)'s current EBIT is kr5 Mil. Overall, Meds Apotek AB (publ) has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Meds Apotek AB (publ)'s EBIT compare to AMZN and BABA?
Meds Apotek AB (publ)'s EBIT of kr5 Mil can be compared against companies in the Retail - Cyclical industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Retail - Cyclical company?
A good EBIT depends on the Retail - Cyclical industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Meds Apotek AB (publ). Meds Apotek AB (publ)'s current EBIT is kr5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Meds Apotek AB (publ) stock overvalued right now?
Meds Apotek AB (publ) (OSTO:MEDS) has a current EBIT of kr5 Mil. The current EBIT is kr5 Mil. Meds Apotek AB (publ)'s overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Meds Apotek AB (publ) (OSTO:MEDS), the current EBIT is kr5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Meds Apotek AB (publ) Business Description

Address Elektravagen 26, Port 136, Hagersten, Stockholm, SWE, 12630
Meds Apotek AB (publ) is a full-scale online pharmacy that sells prescription and over-the-counter medicines with permission from the Medical Products Agency, the Swedish Food Agency and the E-Health Agency. The company's pharmacy products include everything in health, well-being, dietary supplements, beauty products, children's products, fitness products, food and drink and home & household products.
11GF Score

Get the complete analysis for OSTO:MEDS

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr25.20
Price